NO952160L - Humanized antibodies reactive with L-selectin - Google Patents

Humanized antibodies reactive with L-selectin

Info

Publication number
NO952160L
NO952160L NO952160A NO952160A NO952160L NO 952160 L NO952160 L NO 952160L NO 952160 A NO952160 A NO 952160A NO 952160 A NO952160 A NO 952160A NO 952160 L NO952160 L NO 952160L
Authority
NO
Norway
Prior art keywords
selectin
humanized antibodies
antibodies reactive
reactive
humanized
Prior art date
Application number
NO952160A
Other languages
Norwegian (no)
Other versions
NO952160D0 (en
Inventor
Man Sung Co
Original Assignee
Protein Design Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protein Design Labs Inc filed Critical Protein Design Labs Inc
Publication of NO952160D0 publication Critical patent/NO952160D0/en
Publication of NO952160L publication Critical patent/NO952160L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO952160A 1992-12-01 1995-05-31 Humanized antibodies reactive with L-selectin NO952160L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98394692A 1992-12-01 1992-12-01
PCT/US1993/011612 WO1994012215A1 (en) 1992-12-01 1993-11-30 Humanized antibodies reactive with l-selectin

Publications (2)

Publication Number Publication Date
NO952160D0 NO952160D0 (en) 1995-05-31
NO952160L true NO952160L (en) 1995-07-31

Family

ID=25530200

Family Applications (1)

Application Number Title Priority Date Filing Date
NO952160A NO952160L (en) 1992-12-01 1995-05-31 Humanized antibodies reactive with L-selectin

Country Status (12)

Country Link
EP (1) EP0671951A4 (en)
JP (1) JPH08503617A (en)
KR (1) KR100371784B1 (en)
AU (1) AU689090B2 (en)
CA (1) CA2149025A1 (en)
CZ (1) CZ140195A3 (en)
FI (1) FI952658A0 (en)
HU (1) HUT71790A (en)
NO (1) NO952160L (en)
PL (1) PL309249A1 (en)
RU (1) RU2151612C1 (en)
WO (1) WO1994012215A1 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6010861A (en) * 1994-08-03 2000-01-04 Dgi Biotechnologies, Llc Target specific screens and their use for discovering small organic molecular pharmacophores
WO1996040942A1 (en) * 1995-06-07 1996-12-19 Cytel Corporation Humanized antibodies to e-selectin
AU746888B2 (en) * 1995-08-17 2002-05-02 Protein Design Labs, Inc. Anti-selectin antibodies for prevention of multiple organ failure and acute organ damage
JP3604699B2 (en) * 1995-08-17 2004-12-22 プロテイン デザイン ラブス， インコーポレイティド Anti-selectin antibodies for prevention of multiple organ failure after multiple trauma and for prevention of acute organ damage after extracorporeal blood circulation
AU4594297A (en) * 1996-09-27 1998-04-17 Trustees Of Columbia University In The City Of New York, The Methods for treating an ischemic disorder and improving stroke outcome
US8128963B2 (en) 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
EP0852951A1 (en) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stable lyophilized monoclonal or polyclonal antibodies containing pharmaceuticals
WO1999043353A2 (en) * 1998-02-26 1999-09-02 Boehringer Ingelheim Pharmaceuticals, Inc. Combination anti-selectin and immunosuppressant therapy
US20020029391A1 (en) * 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
UY28886A1 (en) * 2004-05-10 2005-12-30 Boehringer Ingelheim Int ANTIBODIES CONSISTING IN POLYPEPTIDES AND DERIVATIVES UNDERSTANDING THREE SEQUENCES CONCERNING THE FOLLOWING NUMBERS OF SEQ. ID: 1-3 AND 4-6; 7-9 AND 10-12 AND 13-15 OR 16-18
WO2007114319A1 (en) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha Method for control of blood kinetics of antibody
CN101500608A (en) 2006-06-08 2009-08-05 中外制药株式会社 Preventive or remedy for inflammatory disease
CN101874042B9 (en) 2007-09-26 2019-01-01 中外制药株式会社 Method for changing isoelectric point of antibody by using amino acid substitution of CDR
WO2009041613A1 (en) 2007-09-26 2009-04-02 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
CA2708065C (en) 2007-12-05 2015-02-24 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for pruritus
ES2834741T3 (en) 2007-12-05 2021-06-18 Chugai Pharmaceutical Co Ltd Anti-NR10 antibody and its use
LT2708559T (en) 2008-04-11 2018-06-11 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
KR20160062207A (en) * 2008-12-05 2016-06-01 추가이 세이야쿠 가부시키가이샤 Anti-NR10 antibody and use thereof
JP2010210772A (en) * 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd Method of manufacturing liquid crystal display device
EP2409991B1 (en) 2009-03-19 2017-05-03 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
TWI544077B (en) 2009-03-19 2016-08-01 Chugai Pharmaceutical Co Ltd Antibody constant region change body
CA2806233C (en) * 2010-07-26 2021-12-07 Trianni, Inc. Transgenic animals and methods of use
NZ606824A (en) 2010-08-02 2015-05-29 Regeneron Pharma Mice that make binding proteins comprising vl domains
EP2647706B1 (en) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
EP2654781B1 (en) * 2010-12-21 2018-01-24 Selexys Pharmaceuticals Corporation Anti-p-selectin antibodies and methods of their use and identification
PL2578688T5 (en) 2011-02-25 2023-05-29 Regeneron Pharmaceuticals, Inc. ADAM6 mice
MY172718A (en) 2011-08-05 2019-12-11 Regeneron Pharma Humanized universal light chain mice
CA2859408C (en) 2011-12-20 2020-06-16 Regeneron Pharmaceuticals, Inc. Humanized light chain mice
KR102436654B1 (en) 2012-06-12 2022-08-26 리제너론 파마슈티칼스 인코포레이티드 Humanized non-human animals with restricted immunoglobulin heavy chain loci
AU2015231025A1 (en) 2014-03-21 2016-09-15 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
KR102601491B1 (en) 2014-03-21 2023-11-13 리제너론 파마슈티칼스 인코포레이티드 Non-human animals that make single domain binding proteins
CN107438622A (en) 2015-03-19 2017-12-05 瑞泽恩制药公司 Non-human animals selected for antigen-binding light chain variable regions
BR112017022101A2 (en) 2015-04-14 2018-07-31 Chugai Seiyaku Kabushiki Kaisha pharmaceutical composition for prevention and / or treatment of atopic dermatitis containing il-31 antagonist as an active ingredient
BR112022006590A2 (en) 2019-11-20 2022-06-28 Chugai Pharmaceutical Co Ltd PREPARATION CONTAINING ANTIBODIES
WO2024194605A1 (en) 2023-03-17 2024-09-26 Quell Therapeutics Limited Treg therapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
NZ236792A (en) * 1990-01-19 1993-05-26 Merck & Co Inc Recombinant human anti-cd18 antibody, murine 1b4 heavy or light chain variable region, dna, vectors, mammalian host and pharmaceutical compositions

Also Published As

Publication number Publication date
PL309249A1 (en) 1995-10-02
WO1994012215A1 (en) 1994-06-09
FI952658A (en) 1995-05-31
HU9501564D0 (en) 1995-07-28
RU2151612C1 (en) 2000-06-27
NO952160D0 (en) 1995-05-31
AU689090B2 (en) 1998-03-26
EP0671951A4 (en) 1997-05-21
CZ140195A3 (en) 1996-06-12
HUT71790A (en) 1996-02-28
CA2149025A1 (en) 1994-06-09
FI952658A0 (en) 1995-05-31
JPH08503617A (en) 1996-04-23
EP0671951A1 (en) 1995-09-20
AU5732794A (en) 1994-06-22
KR100371784B1 (en) 2003-07-22

Similar Documents

Publication Publication Date Title
NO952160L (en) Humanized antibodies reactive with L-selectin
SG48420A1 (en) Humanized antibodies and uses thereof
IL104620A (en) Humanized monoclonal antibodies against human interleukin-5
AU4618193A (en) Humanized antibodies
DE69324596D1 (en) RECOMBINANT HUMANIZED ANTI-CYTOMEGALOVIRUS ANTIBODIES
GB9015908D0 (en) Multivalent immunoglobulin
EP0578515A3 (en) Humanized monoclonal antibodies.
AU5732694A (en) Humanized antibodies reactive with cd18
EP0580859A4 (en) Anti-eda monoclonal antibody
GB8910395D0 (en) Human monoclonal antibody and hybridoma producing the same
IL90017A0 (en) Monoclonal antibodies
ZA898777B (en) Monoclonal antibodies
EP0506523A3 (en) Monoclonal antibodies
IL92232A0 (en) Anti-fucosylceramide monoclonal antibody
ZA89258B (en) Monoclonal antibodies
GB8820036D0 (en) Monoclonal antibodies
GB9223676D0 (en) Modified antibodies
ZA912136B (en) Anti-oncostatin m monoclonal antibodies
IE901210L (en) Monoclonal antibody
IE900922L (en) Monoclonal antibody
IE900593L (en) Monoclonal antibodies
SG64332A1 (en) Monoclonal antibody
GB9212074D0 (en) Monoclonal antibody
FI925804A (en) IMMUNOLOGICAL REACTIVE FOERENING
AU8547291A (en) Monoclonal antibodies against tenascin